SEC Form 4 · accession 0001628280-26-045839
Contineum Therapeutics, Inc. · CTNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Evert B. Schimmelpennink
Director
Period of report
Jun 26, 2026
Accepted (ET)
Jun 26, 2026 · 5:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001855175
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.19 | Jun 26, 2026 | A | 19,000 | A | — | Jun 25, 2036 | Class A Common Stock | 19,000 | 19,000 | D |
Explanation of responses
- F1Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.